Boston Scientific Q2 2026: 7% Organic Growth, $800M Restructuring, Penumbra Deal Advances
BSX is trading near its 52-week low of $42.2 (12% above the low).
Summary
Boston Scientific posted Q2 2026 results with 7.0% organic growth and a new $700M–$800M restructuring plan. The Penumbra acquisition is progressing, and a $2B buyback was completed.
Key Events · Earnings and Guidance · BSX
-
Q2 2026 Results Beat
Net sales of $5.442B (7.0% organic growth) and adjusted EPS of $0.86, driven by Interventional Cardiology and Electrophysiology. Gross margin expanded to 70.7%.
-
Major Restructuring Announced
Board approved a $700M–$800M global restructuring plan on July 21, 2026, targeting $500M in annual pre-tax savings. Charges will be incurred through 2029, with most savings reinvested in growth.
-
Penumbra Acquisition Update
The $14.5B acquisition of Penumbra received FTC Second Request; stockholder vote passed. Closing expected in H2 2026, funded by $11B in new debt and stock.
-
$2B Share Buyback Completed
An accelerated share repurchase agreement settled in June, retiring approximately 40 million shares. $3B remains under the $5B authorization.
Analysis · BSX · Industrial Applications And Services
A solid quarter delivered 7.0% organic sales growth and gross margin expansion to 70.7%, but the spotlight shifts to the sweeping restructuring plan approved just after quarter-end. The $700M–$800M program aims to cut $500M in annual costs, signaling a major operational overhaul. Meanwhile, the $14.5B Penumbra acquisition remains on track for H2 2026 despite an FTC Second Request, and the company deployed $2B in share buybacks. Litigation noise persists with a securities class action and $76M in charges, though a key patent case was won on appeal. The quarter itself was strong, but the restructuring and M&A updates will dominate the narrative.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 35.8% of the 1190 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.45%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BSX was trading at $47.12 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $69.5B. The 52-week trading range was $42.20 to $109.50. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.